Gram-negative Neisseria meningitidis (N.men) is an important contributor to bacterial meningitis. Of the estimated 1.2 million cases which occur each year (WHO Figures), N.men is thought to be responsible for around 40% of the total where 5 main serogroups ACWY and B are responsible for the majority of disease.
Conjugated vaccines to prevent meningococcal disease have had successful impact especially in the United Kingdom (serogroup C, implemented 1999). In 2005, a newer quadrivalent conjugated vaccine with protection against ACWY serogroups, Menactra (MCV4) was recommended for use in US adolescents. To expand the market further new ACWY vaccines such as MenHibrix (GSK), Menveo (Novartis) and also Menactra (Sanofi Pasteur) are aiming for use in infants/toddlers. Because of high competition, complex considerations in terms of schedule inclusion and cost-effectiveness, the US market for ACWY will become increasingly sophisticated where success will be governed by newer variables.
This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all products within all age group indications in the critical US market for the next 10-15 years. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing recommendation/competitive and pricing scenarios.
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 15.0%.
Please review the TERMS and CONDITIONS of purchase.
